menu
    • menu
    [{"orgOrder":0,"company":"Hanall Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"HL161ANS","moa":"FcRn","graph1":"Immunology","graph2":"Preclinical","graph3":"Hanall Biopharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"Hanall Biopharma \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Hanall Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"Hanall Biopharma","sponsor":"Nona Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Batoclimab","moa":"","graph1":"Immunology","graph2":"Phase III","graph3":"Hanall Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Hanall Biopharma \/ Harbour BioMed","highestDevelopmentStatusID":"10","companyTruncated":"Hanall Biopharma \/ Harbour BioMed"},{"orgOrder":0,"company":"Hanall Biopharma","sponsor":"Daewoong Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Tanfanercept","moa":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Hanall Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution\/Drops","sponsorNew":"Hanall Biopharma \/ Daewoong Pharmaceutical","highestDevelopmentStatusID":"10","companyTruncated":"Hanall Biopharma \/ Daewoong Pharmaceutical"},{"orgOrder":0,"company":"Hanall Biopharma","sponsor":"NurrOn Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Agreement","leadProduct":"ATH-399A","moa":"","graph1":"Neurology","graph2":"Preclinical","graph3":"Hanall Biopharma","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Hanall Biopharma \/ HanAll Biopharma","highestDevelopmentStatusID":"4","companyTruncated":"Hanall Biopharma \/ HanAll Biopharma"},{"orgOrder":0,"company":"Hanall Biopharma","sponsor":"Vincere Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Neurology","graph2":"Discovery","graph3":"Hanall Biopharma","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Hanall Biopharma \/ HanAll Biopharma","highestDevelopmentStatusID":"2","companyTruncated":"Hanall Biopharma \/ HanAll Biopharma"},{"orgOrder":0,"company":"Hanall Biopharma","sponsor":"Daewoong Pharmaceutical","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"HL192","moa":"","graph1":"Neurology","graph2":"Phase I","graph3":"Hanall Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Hanall Biopharma \/ Daewoong Pharmaceutical","highestDevelopmentStatusID":"6","companyTruncated":"Hanall Biopharma \/ Daewoong Pharmaceutical"},{"orgOrder":0,"company":"Hanall Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Tanfanercept","moa":"","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Hanall Biopharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Hanall Biopharma \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Hanall Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"Hanall Biopharma","sponsor":"Turn Biotechnologies","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"","productType":"Cell and Gene therapy","year":"2024","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"","graph1":"Ophthalmology","graph2":"Discovery Platform","graph3":"Hanall Biopharma","amount2":0.29999999999999999,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Ophthalmology","amount2New":0.29999999999999999,"dosageForm":"","sponsorNew":"Hanall Biopharma \/ Turn Biotechnologies","highestDevelopmentStatusID":"3","companyTruncated":"Hanall Biopharma \/ Turn Biotechnologies"}]

    Find Clinical Drug Pipeline Developments & Deals by Hanall Biopharma

    Menu

    Hanall Biopharma

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Hanall Biopharma

                            South Korea arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Hanall Biopharma

                            South Korea arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Ophthalmology

                            Study Phase : Discovery Platform

                            Sponsor : Turn Biotechnologies

                            Deal Size : $300.0 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            HanAll Signs Licensing Agreement with Turn Biotechnologies for Eye and Ear Treatments

                            Details : The collaboration aims to leverage HanAll's extensive expertise in ophthalmic and otic diseases and Turn Bio's cellular reprogramming technology to create innovative therapies.

                            Brand Name : Undisclosed

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Undisclosed

                            May 28, 2024

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Discovery Platform

                            Sponsor : Turn Biotechnologies

                            Deal Size : $300.0 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Hanall Biopharma

                            South Korea arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Hanall Biopharma

                            South Korea arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tanfanercept

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            HanAll Biopharma Begins Phase 3 VELOS-4 Trial for Tanfanercept in Dry Eye Disease

                            Details : HK036 (tanfanercept) is a potentially first-in-class topical anti-inflammatory treatment targeting tumor necrosis factor (TNF). It is being evaluated for the treatment of dry eye disease.

                            Brand Name : HL036

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            May 03, 2024

                            Lead Product(s) : Tanfanercept

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase III

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Hanall Biopharma

                            South Korea arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Hanall Biopharma

                            South Korea arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : HL192

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Sponsor : Daewoong Pharmaceutical

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            HanAll Biopharma, Daewoong Pharmaceutical and NurrOn Pharmaceuticals Initiate First-in-Human Phase 1 Clinical ...

                            Details : HL192 (ATH-399A) is a first-in-class small molecule that focuses on activating Nurr1, a master regulator associated with the development and maintenance of dopaminergic neurons, for the potential treatment of Parkinson's Disease.

                            Brand Name : HL192

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            October 12, 2023

                            Lead Product(s) : HL192

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Sponsor : Daewoong Pharmaceutical

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Hanall Biopharma

                            South Korea arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Hanall Biopharma

                            South Korea arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Neurology

                            Study Phase : Discovery

                            Recipient : Vincere Biosciences

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Vincere Biosciences Announces Strategic Investment From Daewoong Pharmaceutical and HanAll Biopharma to Foster...

                            Details : The collaboration aims to develop small-molecule, first-in-class disease-modifying therapies by targeting the modulation of mitochondrial quality control mechanisms such as mitophagy for Parkinson's patients by leveraging Vincere's proprietary AI platfor...

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            June 12, 2023

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Neurology

                            Highest Development Status : Discovery

                            Recipient : Vincere Biosciences

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Hanall Biopharma

                            South Korea arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Hanall Biopharma

                            South Korea arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ATH-399A

                            Therapeutic Area : Neurology

                            Study Phase : Preclinical

                            Recipient : NurrOn Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            HanAll Biopharma and Daewoong Pharmaceutical Enter into Co-Development Agreement with NurrOn Pharmaceuticals t...

                            Details : HanAll Biopharma and Daewoong Pharmaceutical will co-develop NurrOn Pharmaceuticals' novel investigational compounds, including its lead asset ATH-399A, targeting Nurr1 for the treatment of Parkinson's disease (PD), as well as other neurodegenerative dis...

                            Brand Name : ATH-399A

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            May 25, 2023

                            Lead Product(s) : ATH-399A

                            Therapeutic Area : Neurology

                            Highest Development Status : Preclinical

                            Recipient : NurrOn Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Hanall Biopharma

                            South Korea arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Hanall Biopharma

                            South Korea arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tanfanercept

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase III

                            Sponsor : Daewoong Pharmaceutical

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            HanAll Biopharma Announces Results from Phase III Randomized, Double-Masked Active Treatment-Controlled VELOS-...

                            Details : HL036 (tanfanercept) is a novel, potentially first-in-class topical anti-inflammatory treatment targeting tumor necrosis factor alpha for the treatment of dry eye disease, co-developed with Daewoong Pharmaceutical.

                            Brand Name : HL036

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            May 19, 2023

                            Lead Product(s) : Tanfanercept

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase III

                            Sponsor : Daewoong Pharmaceutical

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Hanall Biopharma

                            South Korea arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Hanall Biopharma

                            South Korea arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Batoclimab

                            Therapeutic Area : Immunology

                            Study Phase : Phase III

                            Sponsor : Nona Biosciences

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            HanAll Biopharma's Licensed Partner in China Announces Positive Topline Phase 3 Results for Batoclimab in Myas...

                            Details : IMVT-1401 (batoclimab) is a fully human, subcutaneously administered antibody originated from HanAll, which selectively binds to and inhibits the neonatal Fc receptor (FcRn). It has demonstrated high potential as a new treatment option for gMG patients.

                            Brand Name : IMVT-1401

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            March 06, 2023

                            Lead Product(s) : Batoclimab

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase III

                            Sponsor : Nona Biosciences

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Hanall Biopharma

                            South Korea arrow
                            Medlab Asia & Asia Health
                            Not Confirmed

                            Hanall Biopharma

                            South Korea arrow
                            Medlab Asia & Asia Health
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : HL161ANS

                            Therapeutic Area : Immunology

                            Study Phase : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            HanAll's Second FcRn Inhibitor HL161ANS to be Added to the Development Program of its Licensed Partner

                            Details : Immunovant, a HanAll's licensed partner, unveiled its plan to develop a new FcRn inhibitor, HL161ANS (also known as IMVT-1402). In animal studies, HL161ANS indicated deep IgG reductions similar to batoclimab with no or minimal impact on albumin and LDL c...

                            Brand Name : IMVT-1402

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            October 05, 2022

                            Lead Product(s) : HL161ANS

                            Therapeutic Area : Immunology

                            Highest Development Status : Preclinical

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth